Harmony Biosciences Holdings (HRMY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.98B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harmony Biosciences Holdings (HRMY) P/E Ratio & Valuation History
Harmony Biosciences Holdings (HRMY) trades at 9.6x trailing earnings and 1.9x sales. Its P/E of 9.6x is below its 5-year median of 10.9x. Its forward P/E is 8.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 14.3% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 9.6x |
| Forward P/E | 8.4x |
| Price to sales | 1.9x |
| Price to book | 1.8x |
| EV/EBITDA | 5.9x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 9.6x | 10.9x | N/A |
| P/S | 1.9x | 3.1x | N/A |
| P/B | 1.8x | 3.6x | N/A |
Valuation History
Over the 5 of the 6 year ends shown that have a P/E, its P/E ranged from 8.5x in 2024 to 51.4x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $37.42 | 11.2x | 2.5x | 2.5x |
| 2024 | $34.41 | 8.5x | 2.8x | 3.0x |
| 2023 | $32.30 | 11.4x | 3.3x | 4.1x |
| 2022 | $55.10 | 19.5x | 7.5x | 8.4x |
| 2021 | $42.64 | 51.4x | 8.1x | 13.8x |
| 2020 | $36.15 | N/A | 10.4x | 21.2x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HRMY
What is HRMY's forward P/E ratio?
Harmony Biosciences Holdings has a forward P/E ratio of 8.4x.
Is HRMY stock overvalued?
GNG's valuation label for HRMY is Undervalued.
What is HRMY's price to sales ratio?
Harmony Biosciences Holdings has a price to sales ratio of 1.9x.
What is Harmony Biosciences Holdings's average P/E ratio over 5 years?
Harmony Biosciences Holdings's median P/E over the last 5 years is 10.9x, from 60 month-end values through Oct 2026.
HRMY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts